Showing results (561-570 of 632) with videos related to
Sort By:
Pageof 64
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2023
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional TrialDaniel J Krauss, Theodore Karrison, Alvaro A Martinez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate CancerLe Zhang, Pai-Chi Teng, Karen A Cavassani, et al.European Urology Oncology|July 13, 2023
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily IrradiationDouglas M Dahl, Theodore G Karrison, M Dror Michaelson, et al.International Journal of Radiation Oncology, Biology, Physics|April 9, 2019
Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical TrialsChristopher L Hallemeier, Peixin Zhang, Thomas M Pisansky, et al.Journal of the National Cancer Institute|March 21, 2022
Quantitative Nodal Burden and Mortality Across Solid CancersAnthony T Nguyen, Michael Luu, Vina P Nguyen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical TrialJeff M Michalski, Kathryn A Winter, Bradley R Prestidge, et al.European Urology|May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 TrialOliver Sartor, Theodore G Karrison, Howard M Sandler, et al.The Prostate|July 21, 2025
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following ProstatectomyEmily Chan, Stephanie L Pugh, Jeffry P Simko, et al.European Urology|June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601William C Jackson, Ming Tang, Matthew J Schipper, et al.Pageof 64